PubMed Health⌕ Search

PubMed · 2533697

Maximum achievable bronchodilatation in asthma.

Abstract

We have examined the effects of combinations of three bronchodilator drugs in 37 patients with poorly reversible asthma. In each case FEV1 was less than 90% predicted before administration of the third drug. Nineteen patients took increasing doses of salbutamol by inhalation followed by 160 micrograms ipratropium bromide and intravenous aminophylline, 5.6 mg kg-1. FEV1 increased by at least 200 ml in 18 patients after salbutamol. Subsequently, ipratropium bromide increased FEV1 by 200 ml in three patients while aminophylline did not produce a further 200 ml rise in any patient in this group. Nine patients were given aminophylline followed by ipratropium bromide and salbutamol and nine took ipratropium bromide then aminophylline and salbutamol. Eleven of the 18 patients in these latter two groups had a 200 ml increase in FEV1 using salbutamol as the third drug. Significant increases in pulse rate were only seen after aminophylline or salbutamol administered as the third drug. These results suggest that maximal bronchodilatation in poorly reversible asthma can usually be achieved by increasing doses of beta agonist up to a therapeutic plateau. A further response, if required, may be achieved in some patients with ipratropium bromide.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Chaieb, N Belcher, P J Rees. 1989. Maximum achievable bronchodilatation in asthma.. https://doi.org/10.1016/s0954-6111(89)80134-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗